A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carb
5 hours ago
- #Olanzapine
- #Antiemetic prophylaxis
- #Chemotherapy-induced nausea and vomiting
- Randomized, double-blind, placebo-controlled trial comparing olanzapine (5 mg) with placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy.
- Primary endpoint: Total protection (mild/no nausea, no vomiting, no rescue therapy) within 120 hours post-chemotherapy.
- Results: Total protection achieved in 71.0% of olanzapine group vs. 55.7% in placebo group (p = 0.06). Total control significantly higher with olanzapine (62.3% vs. 38.6%, p = 0.005).
- Delayed nausea (grade ≥ 2) less frequent with olanzapine (13.0% vs. 30.0%, p = 0.015).
- Patient preference: 95.6% of olanzapine patients preferred to continue the regimen vs. 72.9% of placebo recipients (p = 0.001).
- Conclusion: Olanzapine combined with ondansetron and dexamethasone showed moderate improvement in total protection and significant improvements in no-nausea and total control rates.